Financings
Grey Matters Improves Warrant Terms of Private Placement
Grey Matters Amends Warrant Terms to Secure Financing as Clinic Expansion Nears; Stock Holds Near Issue Price
Executive Summary
- Grey Matters Health Inc. amended terms of a CAD $1,000,000 non-brokered private placement announced on April 22, 2026.
- The amendment removes the warrant acceleration feature (previously triggered if share price exceeded CAD $0.80 for 10 consecutive days).
- Warrant exercise period extended from 24 months to 36 months from issuance date.
- Offering details remain: CAD $0.40 per Unit, consisting of one Class A common share and one Common Share purchase warrant.
- Warrant exercise price set at CAD $0.60 per Warrant Share.
- Proceeds earmarked for advancing the Alzheimer’s Disease program and establishing the first U.S. neuroimaging clinic (Davie, FL).
- Company also signed a non-binding LOI with Catalyst MedTech on May 20, 2026, for minimum 200 brain PET scans at the planned Tampa location.
Material Impact
- The news is an administrative amendment to a financing deal already announced and priced into the market weeks prior (April 22).
- Removing the acceleration clause has minimal immediate financial impact as the current share price ($0.40) is significantly below the trigger price ($0.80), making the clause dormant regardless of the change.
- Extending warrant expiry from 2 to 3 years increases long-term dilution risk for existing shareholders, which is a negative structural factor masked by positive financing news.
- The amendment likely facilitates the closing of the $1M raise by making terms more attractive to investors given the stock's decline from $0.95 to $0.40.
- No new revenue streams or clinical breakthroughs are announced; this is purely capital structure management.
- Given the small size of the raise ($1M CAD) relative to clinic build-out costs, the materiality on operational progress is limited but necessary for survival.
GREY · Price
Company Overview
- Flagship Project: NovaScan Neuroimaging Clinics™ specializing in Alzheimer’s Disease detection using FDA-cleared CareMiBrain system.
- Technology: Stand-alone diagnostic brain PET scanner reducing radiation by 25% compared to conventional systems; open upright environment for patient comfort.
- Locations: Davie, FL (inaugural clinic planned Q3 2026) and Tampa, FL (second location planned end of Q4 2026).
- Business Model: Revenue from direct physician referrals and large-scale CRO services agreements (e.g., Catalyst MedTech trial scans).
More from Grey Matters Health Inc.
Jun 05, 2026 · 16:01